Q32 BioQTTB -1.72%17 Pretax Margin % is % as of Mar. 2026. GuruFocus rates QTTB with a GF Score™ of 17/100. The stock has 6 warning signs investors should review. Among 938 Biotechnology companies, Q32 Bio ranks better than 96.8% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Q32 Bio's Pre-Tax Income for the
three
months ended in Mar. 2026 was $-7.61 Mil. Q32 Bio's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Q32 Bio's pretax margin for the quarter that ended in Mar. 2026 was %.
The historical rank and industry rank for Q32 Bio's Pretax Margin % or its related term are showing as below:
QTTB'
s Pretax Margin % Range Over the Past 10 Years
Min: -642.72 Med: 55.49 Max: 803.26
Current: 61.86
QTTB's Pretax Margin % is ranked better than 96.8% of 938
companies
in the Biotechnology industry
Industry Median: -89.895
vs QTTB: 61.86
Q32 Bio (NAS:QTTB) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Q32 Bio Pretax Margin % Related Terms
Q32 Bio Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Q32 Bio's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
QTTB vs CAMP, CDXS, KROS: Pretax Margin % Comparison
For the Biotechnology subindustry, Q32 Bio's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q32 Bio Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Q32 Bio's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Q32 Bio's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q32 Bio (QTTB) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Q32 Bio and its competitors. According to the industry distribution chart, Q32 Bio ranks #30 out of 938 companies in the Biotechnology industry, placing it in the top 3.2%.
Is Q32 Bio's Pretax Margin % too high?
Q32 Bio's current Pretax Margin % is %. Based on the distribution chart, Q32 Bio ranks #30 out of 938 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's Pretax Margin % compare to CAMP and CDXS?
According to the Biotechnology industry distribution chart, Q32 Bio ranks #30 out of 938 companies for Pretax Margin %. This places Q32 Bio in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Q32 Bio and its competitors. Q32 Bio's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (QTTB) has a current Pretax Margin % of %. The current Pretax Margin % is %. Q32 Bio's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Q32 Bio (QTTB), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score
Get the complete analysis for QTTB
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
QTTB has been successfully added to your 
